UNSPSC 51151533: Aceclidine hydrochloride

This classification denotes the hydrochloride form of a cholinergic agonist with the molecular formula C9H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0578K3ELIO, chemically known as 3-quinuclidinol, acetate (ester) but more generally known as aceclidine, which bears US NIH Compound Identifier 1979. Aceclidine most often comes in forms base, hydrochloride, and salicylate. European Medicines Agency schedules Aceclidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05199MIG.

UNSPSC 51151533 Aceclidine hydrochloride is a Commodity code that spans pharmaceutical active ingredients and finished pharmaceutical products. State and local procurement activity under this code shows a marked disconnect between the nominal code scope and actual recent solicitation content. The two recent opportunities tagged to this code involve naloxone procurement and direct-to-manufacturer pharmacy benefit programs — neither of which involves aceclidine hydrochloride as a specified product. Issuing bodies include county health departments and state health and human services agencies; the activity does not reflect a cohesive buying pattern around the specific chemical compound the code nominally describes.

The recent opportunities show minimal geographic concentration. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually via competitive bidding with a July 26, 2023 response deadline (note: posted date and due date discrepancy in source). Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for a direct-to-manufacturer prescription program without formal competitive criteria or timelines. The code shows little recent activity genuinely aligned to aceclidine hydrochloride procurement; vendors should verify the actual chemical or therapeutic products state and local agencies are buying before pursuing opportunities tagged to this code, as the recent record suggests classification misalignment rather than active demand for this specific pharmaceutical ingredient.